LifeMD (NASDAQ:LFMD) Chief Financial Officer Atul Kavthekar said the virtual care company is focused on expanding beyond its current weight management base while building insurance capabilities, pharmacy infrastructure and technology tools that management views as competitive advantages.
Kavthekar, who said he joined LifeMD about two months ago, described the company as “one of the leading virtual primary care providers in the nation.” He said LifeMD has had more than 400 million interactions to date and has 322,000 active patients who pay subscriber fees and are prescribed drugs through its platform.
LifeMD Highlights Insurance Expansion and Growth Verticals
Kavthekar said LifeMD’s weight management business, including GLP-1 metabolic health, represents roughly two-thirds of the company’s business and includes about 80,000 patients on therapy. He said the company has “very, very deep” relationships with Novo Nordisk and Eli Lilly, the principal manufacturers of GLP-1 drugs, and expects to benefit as more related drugs enter the market.
Women’s health is smaller today but was described as a significant opportunity. Kavthekar cited gaps in access to care, saying that 50% of women in U.S. counties lack an OBGYN, and said LifeMD is focused on hormonal care and other women’s health products. He also said men’s health remains “very, very profitable,” though it is becoming a smaller share of the business compared with newer growth areas.
One of the areas Kavthekar emphasized most was insurance. He said the company is transitioning from a business that is currently mostly cash pay toward greater insurance coverage for care visits. He said LifeMD expects to be able to provide insurance coverage for the care portion of services for “virtually anyone in the country” who needs certain drugs, though he noted many drugs may not be covered by insurance.
In response to an analyst question, Kavthekar said patients generally pay cash today through platform fees and drug purchases, either through LifeMD or their own pharmacy. For insured care, LifeMD bills the payer similarly to a brick-and-mortar doctor visit, with patient costs depending on the plan. He said Medicare expansion is also being evaluated, and that CMS is expected to expand GLP-1 coverage for weight loss through a program involving an appointed third-party administrator.
LifeMD Reiterates 2025 Guidance
Kavthekar said LifeMD is guiding for revenue of $220 million to $230 million and adjusted the EBITDA guidance on the presentation slide, saying it should be $12 million to $17 million. He also said the company expects to exit the year at a run rate closer to $250 million in revenue and $25 million of EBITDA.
He said LifeMD is debt-free and has “a lot of cash on the balance sheet.” Kavthekar added that the company monitors patient retention, lifetime value and customer acquisition costs closely, which he said allows LifeMD to grow without necessarily needing to raise new capital and dilute shareholders.
SINTX Presents Silicon Nitride Medical Device Strategy
SINTX President Ryan Elmore also presented, describing the company as a medical device business built around silicon nitride, a ceramic biomaterial. Elmore contrasted silicon nitride with titanium and PEEK, saying titanium performs well with bone but can struggle in active infections, while PEEK has limitations in bone on-growth and infection resistance.
Elmore said silicon nitride can resist infection through nitrogen-related molecules released from the material, while also stimulating mitochondrial activity in animal cells and increasing osteoblast activity. He emphasized that silicon nitride is not an antibiotic and said the company believes that distinction avoids issues related to antibiotic resistance.
SINTX is developing silicon nitride in several forms, including pure monolithic ceramic, silicon nitride composites such as silicon nitride PEEK, and coatings for metal devices. Elmore said the company is initially targeting extremities, particularly foot and ankle products, because the segment is growing and can support patient-specific implants.
SINTX Discusses FDA Clearance, Launch Plans and Capital Position
Elmore said SINTX received FDA 510(k) clearance last fall for its foot and ankle wedge system and performed its first case in March. He said the company is in a limited user release and expects a full launch for Evans, Cotton and subtalar wedges by the fourth quarter of this year. He said about 71 surgeons have given verbal commitments to use the product when available.
Elmore said the foot and ankle wedge market is roughly $50 million to $60 million and includes competitors such as Stryker. He said SINTX’s wedge uses the same shape and size as metal or PEEK implants, so surgeons do not need special training to use it.
Gregg Honigblum, SINTX’s chief investment officer, said the company has no debt and access to about $5.1 million through an at-the-market offering. He said the company’s cash burn is currently about $800,000 per month but is expected to decline as legacy industrial contracts contribute revenue. Elmore said SINTX’s three-year projections put the company at cash-flow positive by year three, with a potential path to about $22 million in revenue by that time.
About LifeMD (NASDAQ:LFMD)
LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.
LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.
